Acne vulgaris is the most common dermatologic disorder in the United States and also in a large part of developed countries in the world. Although its cause is unknown, various factors are implicated in its pathogenesis. No single topical antiacne medication acts on all the major pathophysiologic events. Combined use of agents with different modes of action provides better patient outcomes than monotherapy.
Many medications are available for the management of acne. The armamentarium includes topical retinoids (ie, adapalene, tazarotene, tretinoin), antimicrobial and antibacterial agents (ie, benzoyl peroxide, clindamycin, erythromycin, sulfacetamide with or without sulfur), oral antibiotics (ie, doxycycline, minocycline, tetracycline), hormonal agents (ie, oral contraceptives, spironolactone), and systemic retinoids (ie, isotretinoin). Acne usually is treated with combination therapy to address its multifactorial pathophysiology.
The product’s excipients, glycerin and dimethicone, minimize treatment-related irritation, thereby increasing patient compliance. An efficient cosmetic choice is essential to maximize results.
Topical antibiotics and benzoyl peroxide, are the two main topical antibacterial treatments indicated for mild-to-moderate acne vulgaris. Topical antibiotics act both as antibacterial agents suppressing Propionibacterium acnes in the sebaceous follicle and as anti-inflammatory agents.
If no improvement is observed within 6-8 weeks, the agent should be discontinued and a therapeutic switch considered.
Antibacterial therapy can be used in combination with other agents. Combining topical antibiotics and topical retinoids may enhance the efficacy, since the retinoid will improve the penetration of the antibiotic.
About the Author